MCID: PHC013
MIFTS: 43

Phaeochromocytoma

Categories: Cancer diseases

Aliases & Classifications for Phaeochromocytoma

MalaCards integrated aliases for Phaeochromocytoma:

Name: Phaeochromocytoma 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050771

Summaries for Phaeochromocytoma

MalaCards based summary : Phaeochromocytoma is related to multiple endocrine neoplasia, type iia and ganglioneuroma. An important gene associated with Phaeochromocytoma is MEG3 (Maternally Expressed 3
Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas,10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element.
Dysfunction Pattern: Regulation [down-regulated]), and among its related pathways/superpathways are Carbon metabolism and Neuroscience. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, testes and thyroid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Pheochromocytoma (PCC) is a neuroendocrine tumor of the medulla of the adrenal glands (originating in... more...

Related Diseases for Phaeochromocytoma

Diseases related to Phaeochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iia 32.1 NF1 RET SDHB SDHD
2 ganglioneuroma 30.3 CHGA RET
3 thyroid carcinoma, familial medullary 30.2 CHGA RET SST
4 somatostatinoma 30.0 CHGA SST
5 gastrinoma 29.8 CHGA SST
6 cystadenoma 29.5 CHGA VHL
7 multiple endocrine neoplasia 29.2 CHGA NF1 RET SDHB SDHC VHL
8 neurofibromatosis, type iv, of riccardi 29.0 NF1 RET SDHB SDHC SDHD VHL
9 clear cell renal cell carcinoma 28.9 MEG3 TMEM127 VHL
10 serotonin syndrome 28.9 CHGA SST
11 von hippel-lindau syndrome 27.7 CHGA NF1 NPY RET SDHB SDHC
12 paraganglioma 25.8 CHGA NF1 RET SDHAF2 SDHB SDHC
13 multiple endocrine neoplasia, type iib 11.0
14 glomus tumor 10.7 SDHB SDHD
15 pancreatic serous cystadenoma 10.6 CHGA VHL
16 epithelioid malignant peripheral nerve sheath tumor 10.6 CHGA NF1
17 gastrointestinal neuroendocrine benign tumor 10.5 CHGA SST
18 adenoma of the pancreas 10.5 CHGA SST
19 gastric neuroendocrine neoplasm 10.5 CHGA SST
20 gastrointestinal neuroendocrine tumor 10.5 CHGA SST
21 malignant glandular tumor of peripheral nerve sheath 10.4 NF1 SST
22 spinal meningioma 10.4 CHGA NF1
23 glucagonoma 10.4 CHGA SST
24 hyperinsulinemic hypoglycemia, familial, 2 10.4 CHGA SST
25 spinal canal and spinal cord meningioma 10.4 CHGA NF1
26 vipoma 10.4 CHGA SST
27 pancreatoblastoma 10.4 CHGA SST
28 duodenal somatostatinoma 10.4 NF1 SST
29 paragangliomas 1 10.4 SDHB SDHC SDHD
30 chondroma 10.4 SDHB SDHC SDHD
31 paraganglioma and gastric stromal sarcoma 10.4 SDHB SDHC SDHD
32 duodenal gastrinoma 10.4 CHGA SST
33 carney triad 10.4 SDHB SDHC SDHD
34 breast papillary carcinoma 10.4 CHGA RET
35 lymphatic system disease 10.4 SDHB SDHC SDHD
36 binswanger's disease 10.4 CHGA SST
37 zollinger-ellison syndrome 10.4 CHGA SST
38 ectopic cushing syndrome 10.4 RET SST
39 hypertrophic pyloric stenosis 10.3 RET SST
40 familial renal papillary carcinoma 10.3 NGF RET
41 cortical thymoma 10.2 NGF SST
42 prolactin producing pituitary tumor 10.2 NGF SST
43 mixed ductal-endocrine carcinoma 10.2 CHGA SST
44 cell type benign neoplasm 10.2 CHGA RET SST
45 carcinoid tumors, intestinal 10.2 CHGA SDHD SST
46 islet cell tumor 10.2 CHGA SST
47 thyroid cancer, nonmedullary, 2 10.2 CHGA RET SST
48 neuroendocrine tumor 10.2 CHGA SDHD SST
49 constipation 10.1 NPY RET SST
50 goldberg-shprintzen syndrome 10.1 NGF RET

Graphical network of the top 20 diseases related to Phaeochromocytoma:



Diseases related to Phaeochromocytoma

Symptoms & Phenotypes for Phaeochromocytoma

GenomeRNAi Phenotypes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.9 VHL NF1 RET SDHD
2 Decreased viability GR00221-A-2 9.9 VHL NF1 RET SDHD
3 Decreased viability GR00221-A-4 9.9 NF1 RET SDHD
4 Decreased viability GR00231-A 9.9 RET
5 Decreased viability GR00301-A 9.9 RET VHL
6 Decreased viability GR00381-A-1 9.9 SDHD
7 Decreased viability GR00402-S-2 9.9 NF1 RET SDHD VHL
8 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 NF1 VHL

MGI Mouse Phenotypes related to Phaeochromocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 CHGA NF1 NGF NPY RET SDHB
2 mortality/aging MP:0010768 9.97 SDHC SDHD SST VHL CHGA NF1
3 cardiovascular system MP:0005385 9.95 CHGA NF1 NGF RET SDHB SDHD
4 neoplasm MP:0002006 9.65 NF1 RET SDHB SDHD VHL
5 no phenotypic analysis MP:0003012 9.63 CHGA NGF RET SDHB SST TMEM127
6 normal MP:0002873 9.56 NF1 NGF NPY RET SDHB SDHD
7 renal/urinary system MP:0005367 9.1 CHGA NF1 NPY RET SDHB VHL

Drugs & Therapeutics for Phaeochromocytoma

Drugs for Phaeochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 3,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
5 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
6 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
7 Antihypertensive Agents Phase 4,Phase 3,Phase 2
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Vasodilator Agents Phase 4,Phase 3,Phase 2
10
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
11
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
12
Ifosfamide Approved Phase 3 3778-73-2 3690
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1,Not Applicable
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormone Antagonists Phase 2, Phase 3,Phase 1
19 Hormones Phase 2, Phase 3,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
25
Isophosphamide mustard Phase 3 0
26 Topoisomerase Inhibitors Phase 3,Phase 2
27
Indinavir Approved Phase 2 150378-17-9 5362440
28
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
29
Epinephrine Approved, Vet_approved Phase 2,Not Applicable 51-43-4 5816
30
Racepinephrine Approved Phase 2,Not Applicable 329-65-7 838
31
Carbidopa Approved Phase 2 28860-95-9 34359 38101
32
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
33
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
34
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 7553-56-2 807
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Tamoxifen Approved Phase 2 10540-29-1 2733526
41
Melphalan Approved Phase 2 148-82-3 4053 460612
42
Pancrelipase Approved, Investigational Phase 2,Not Applicable 53608-75-6
43
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
44
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
47
Lenvatinib Approved, Investigational Phase 2 417716-92-8
48
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
49
nivolumab Approved Phase 2 946414-94-4
50
Pembrolizumab Approved Phase 2 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
9 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
12 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
13 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2 Sunitinib
14 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
15 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
16 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
20 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
21 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Completed NCT00088374 Phase 2 17 allylamino-17-demethoxygeldanamycin;18 FDG (Fludeoxyglucose 18F);[15-O] H2O;EPL diluent
22 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
23 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
24 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
25 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;Amino Acid solution
26 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
27 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
28 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
29 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
30 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2 MIBG
31 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
32 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
33 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
34 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
35 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
36 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
37 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
38 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
39 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
42 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
43 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
44 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Unknown status NCT02186678 Not Applicable
47 Evaluation of Plasma Catecholamine Concentration During Surgery Unknown status NCT00948181
48 Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Unknown status NCT02361996
49 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
50 Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing NCT00730444 Iobenguane I 123 Injection

Search NIH Clinical Center for Phaeochromocytoma

Genetic Tests for Phaeochromocytoma

Anatomical Context for Phaeochromocytoma

MalaCards organs/tissues related to Phaeochromocytoma:

41
Adrenal Gland, Testes, Thyroid, Liver, Heart, Kidney, Endothelial

Publications for Phaeochromocytoma

Articles related to Phaeochromocytoma:

(show top 50) (show all 639)
# Title Authors Year
1
Clinical evaluation and treatment of phaeochromocytoma. ( 29027806 )
2018
2
Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. ( 29741215 )
2018
3
Pathology and genetics of phaeochromocytoma and paraganglioma. ( 29239044 )
2018
4
Phaeochromocytoma found on cardiovascular magnetic resonance in a patient presenting with acute myocarditis: an unusual association. ( 29884661 )
2018
5
Most patients undergoing phaeochromocytoma removal could be safely discharged from the post-anaesthesia care unit to the ward after three hours monitoring. ( 29576133 )
2018
6
The challenge of improving the diagnostic yield from metanephrine testing in suspected phaeochromocytoma and paraganglioma. ( 29660998 )
2018
7
The importance of standardisation of measurement and reference intervals for detection of phaeochromocytoma and paraganglioma (PPGL). ( 29460105 )
2018
8
Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis. ( 28746746 )
2017
9
Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. ( 28605116 )
2017
10
Significant decreases in blood propofol concentrations during adrenalectomy for phaeochromocytoma. ( 28548279 )
2017
11
Author's reply to Grocott: Risk of cardiac ischaemia in patients without I+-receptor blockade for phaeochromocytoma surgery. ( 28969332 )
2017
12
Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma? ( 27696513 )
2017
13
Perioperative management of a large, late presenting phaeochromocytoma. ( 28100576 )
2017
14
A rare cause of hypertension in pregnancy: Phaeochromocytoma. ( 28680468 )
2017
15
Phaeochromocytoma and Paraganglioma Excision Involving the Great Vessels. ( 28856331 )
2017
16
Giant phaeochromocytoma presenting with an acute stroke: reappraising phaeochromocytoma surveillance for the neurofibromatosis type 1 phakomatosis. ( 29102976 )
2017
17
Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis. ( 28911298 )
2017
18
Optimal Management of a Synchronous Diagnosis of Phaeochromocytoma and Colorectal Neoplasia. ( 29203998 )
2017
19
Safety assessments in the avoidance of preoperative I+-receptor blockade in phaeochromocytoma surgery: the pitfalls of a zero numerator. ( 28969333 )
2017
20
Concomitant multiple myeloma and probable phaeochromocytoma in a cat. ( 28839945 )
2017
21
Hypertensive emergency masquerading as phaeochromocytoma: a report of two cases. ( 28784870 )
2017
22
Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. ( 29332973 )
2017
23
Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. ( 28179334 )
2017
24
Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas. ( 28693800 )
2017
25
The clinical genetics of phaeochromocytoma and paraganglioma. ( 29166454 )
2017
26
Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. ( 27856506 )
2017
27
Perioperative I+-receptor blockade in phaeochromocytoma surgery: an observational case series. ( 28100521 )
2017
28
A laparoscopic revelation: incidental nodule in a patient with bilateral phaeochromocytoma in multiple endocrine neoplasia Type 2A. ( 29242944 )
2017
29
Bowel perforation complicating an ACTH-secreting phaeochromocytoma. ( 28203371 )
2016
30
Phaeochromocytoma presenting with labile blood pressures following coronary artery bypass grafting. ( 27699857 )
2016
31
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. ( 27048283 )
2016
32
Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A. ( 27994876 )
2016
33
Cardiogenic shock induced by a voluminous phaeochromocytoma rescued by concomitant extracorporeal life support and open left adrenalectomy. ( 27068551 )
2016
34
Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted/seated patients. ( 27166307 )
2016
35
Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. ( 26839173 )
2016
36
Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. ( 27194370 )
2016
37
Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: is it always necessary? ( 27864838 )
2016
38
Phaeochromocytoma presenting as an acute coronary syndrome. ( 27797837 )
2016
39
Phaeochromocytoma presenting with ST segment elevation myocardial infarction. ( 26857585 )
2016
40
Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. ( 26998836 )
2016
41
Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase (SDHx) mutations. ( 27634942 )
2016
42
Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study. ( 26884116 )
2016
43
[Hereditary phaeochromocytoma in twins]. ( 27523316 )
2016
44
Endoprosthetic reconstruction for metastatic phaeochromocytoma in the distal femur: A case report. ( 28018063 )
2016
45
Phaeochromocytoma and Paraganglioma. ( 27888488 )
2016
46
Inappropriate adrenoreceptor blockade prior to phaeochromocytoma removal is perhaps a 'timely reappraisal'? ( 27332792 )
2016
47
ANNALS EXPRESS: Single-centre study of the diagnostic performance of plasma metanephrines with seated sampling for the diagnosis of phaeochromocytoma/paraganglioma. ( 27170024 )
2016
48
Malignant phaeochromocytoma with cavoatrial extension imaged with (123)I-MIBG. ( 26932713 )
2016
49
Primary hypercortisolism and phaeochromocytoma next to, but not related to, each other. ( 27073149 )
2016
50
Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. ( 27075351 )
2016

Variations for Phaeochromocytoma

Expression for Phaeochromocytoma

Search GEO for disease gene expression data for Phaeochromocytoma.

Pathways for Phaeochromocytoma

GO Terms for Phaeochromocytoma

Cellular components related to Phaeochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
2 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.8 SDHB SDHC SDHD

Biological processes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.55 NF1 NGF SST TMEM127 VHL
2 aerobic respiration GO:0009060 9.4 SDHB SDHC
3 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.37 NF1 NGF
4 peripheral nervous system development GO:0007422 9.32 NF1 NGF
5 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.26 NF1 RET
6 mitochondrial electron transport, succinate to ubiquinone GO:0006121 9.13 SDHAF2 SDHC SDHD
7 tricarboxylic acid cycle GO:0006099 8.92 SDHAF2 SDHB SDHC SDHD

Molecular functions related to Phaeochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 electron transfer activity GO:0009055 9.43 SDHB SDHC SDHD
2 ubiquinone binding GO:0048039 9.16 SDHB SDHD
3 succinate dehydrogenase activity GO:0000104 8.96 SDHC SDHD
4 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.8 SDHB SDHC SDHD

Sources for Phaeochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....